Yahoo · Sep 4, 2026
TLX Stock Clocks 5% Gain This Week Ahead Of FDA Decision On Brain Cancer Imaging Agent
The FDA’s target date for deciding on Pixclara is September 11.
TL
NASDAQ · TLX
Telix Pharmaceuticals Limited
Healthcare · Biotechnology
$11.29
Down-$0.61 (-5.13%)
Updated Sep 12, 2026, 4:51 PM
SID Score
5.9/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.18B
- P/E ratio
- 133.11
- Dividend yield
- 0.00%
- 52-week range
- $7.20 – $12.48
- Volume
- 415.34K
- Avg. volume
- 128.55K
Price performance
TLX price history
1M range · 20 trading sessions · Daily adjusted prices
TLX closed at $11.29 after 20 trading sessions, down 4.48% for the selected period.
- Last close
- $11.29
- Period change
- -4.48%
- Period low
- $10.85
- Period high
- $12.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $11.75 | $11.75 | $11.1962 | $11.29 | 415.34K |
| Sep 10, 2026 | $12.10 | $12.20 | $11.88 | $11.90 | 337.79K |
| Sep 9, 2026 | $12.085 | $12.48 | $11.965 | $12.34 | 548.31K |
| Sep 8, 2026 | $12.07 | $12.21 | $11.98 | $11.98 | 336.39K |
| Sep 4, 2026 | $11.84 | $11.95 | $11.84 | $11.94 | 142.01K |
| Sep 3, 2026 | $11.70 | $11.78 | $11.61 | $11.74 | 139.77K |
| Sep 2, 2026 | $11.40 | $11.79 | $11.3801 | $11.45 | 239.37K |
| Sep 1, 2026 | $10.94 | $10.96 | $10.80 | $10.85 | 186.29K |
| Aug 31, 2026 | $11.28 | $11.28 | $11.04 | $11.09 | 121.91K |
| Aug 28, 2026 | $11.47 | $11.47 | $11.2066 | $11.29 | 88.53K |
| Aug 27, 2026 | $11.32 | $11.38 | $11.27 | $11.375 | 73.8K |
| Aug 26, 2026 | $11.26 | $11.34 | $11.07 | $11.13 | 123.3K |
| Aug 25, 2026 | $11.75 | $11.77 | $11.62 | $11.69 | 95.85K |
| Aug 24, 2026 | $11.46 | $11.76 | $11.46 | $11.68 | 266.38K |
| Aug 21, 2026 | $11.34 | $11.39 | $11.19 | $11.33 | 299.63K |
| Aug 20, 2026 | $12.26 | $12.48 | $12.06 | $12.42 | 368.57K |
| Aug 19, 2026 | $12.06 | $12.1846 | $12.00 | $12.12 | 88.73K |
| Aug 18, 2026 | $11.87 | $11.9795 | $11.8382 | $11.88 | 43.11K |
| Aug 17, 2026 | $11.71 | $11.80 | $11.56 | $11.73 | 60.24K |
| Aug 14, 2026 | $11.96 | $11.99 | $11.75 | $11.82 | 120.68K |
Latest TLX news
The latest Smart Investors Daily articles mentioning TLX.
Stock researchCompany · Overview
TLX research
Overview
Company profile and research snapshot.
Company profile
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2026 | Wedbush | Outperform | — |
| Jul 7, 2026 | Citigroup | Buy | — |
| Jul 7, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 6, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Sector Update: Healthcare Stocks Advance Wednesday Afternoon
Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th
Yahoo · Sep 2, 2026
Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway
Telix Pharmaceuticals Ltd ADR (NASDAQ:TLX) shares rose 5. 3% in premarket trading on Wednesday as investors assessed the company’s Phase 3 BiPASS trial progress and its regulatory pathway in the U.
Benzinga · Sep 2, 2026
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
